DSP4, a Selective Neurotoxin for the Locus Coeruleus Noradrenergic System. A Review of Its Mode of Action

Neurotoxicity Research

Volumn 27, Issue 1, 2015, Pages 15-30

  Ross, Svante B ^a   Stenfors, Carina ^a,b  

^a ASTRAZENECA R AND D   (Sweden)

^b ORION CORPORATION   (Finland)

Author keywords

DSP4; Locus coeruleus noradrenaline neurons; N Propargylamines; Rat; Selegiline; Xylamine

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; BENZYLAMINE DERIVATIVE; NEUROTOXIN; NORADRENALIN;

ADRENERGIC NERVE CELL; ANIMAL; CHEMISTRY; DRUG EFFECTS; LOCUS CERULEUS; METABOLISM; MOUSE; RAT; SYNAPTOSOME;

ADRENERGIC NEURONS; ANIMALS; BENZYLAMINES; LOCUS COERULEUS; MICE; NEUROTOXINS; NOREPINEPHRINE; PRESYNAPTIC TERMINALS; RATS;

EID: 84937965850     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-014-9482-z     Document Type: Review

References (108)

1. Alttoa A, Kölv K, Eller M, Uustare A, Rinken A, Harro J (2005) Effects of low doses of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine administrated on exploratory and amphetamine-induced behavior and dopamine D2 receptor function in rats with high or low exploratory activity. Neuroscience 132:979–990
2. Archer T, Fredriksson A (2001) Effects of alpha-adrenoceptor agonists in chronic morphine administered DSP4-treated rats: evidence for functional cross-sensitization. Neurotox Res 3:411–432
3. Archer T, Jonsson G, Ross SB (1984) A parametric study of the effects of the noradrenaline neurotoxin DSP4 on avoidance acquisition and noradrenaline neurons in the CNS of the rat. Br J Pharmacol 82:249–257
4. Asin KE, Wirtshafter D, Fibiger HC (1982) Alteration in drug induced catalepsy and post-decapitation convulsions following brain and spinal cord depletion of norepinephrine by the neurotoxin DSP-4. Life Sci 30:1531–1536
5. Barclay SR, Harding CF, Waterman SA (1996) Central DSP-4 treatment decreases norepinephrine levels and courtship behavior in male zebra finches. Pharmacol Biochem Behav 53:213–220
6. Bitler CM, Zhang MB, Howard BD (1986) PC12 variants deficient in catecholamine transport. J Neurochem 47:1286–1293
7. Booze RM, Hall JA, Cress NM, Miller GD, Davis JN (1988) DSP-4 treatment produces abnormal tyrosine hydroxylase immunoactive fibers in rat hippocampus. Exp Neurol 101:75–86
8. Bortel A (2014) Nature of DSP-4-induced neurotoxicity. In: Kostrzewa RM (ed) Handbook of neurotoxicity. Springer, New York, pp 221–236
9. Bortel A, Nowak P, Brus R (2008) Neonatal DSP-4 treatment modifies GABAergic neurotransmission in the prefrontal cortex in adult rats. Neurotox Res 13:247–252
10. Bortolozzi A, Artigas F (2006) Control of 5-hydroxytryptamine release in the dorsal raphe nucleus by the noradrenergic system in rat brain. Role of alpha-adrenoceptors. Neuropsychopharmacology 28:421–434
11. Cassano T, Gaetani S, Morgese MG, Macheda T, Laconca L, Dispaquale P, Taltavull J, Shippenberg TS, Cuomo V, Gobbi G (2010) Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion. Neurochem Res 34:1417–1426
12. Casteling CB, Schmidt MF (2010) What birdsong can teach us about the central noradrenergic system? J Chem Neuroanat 39:96–111
13. 3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatment. Neuropharmacology 35:63–70
14. 3H]norepinephrine accumulation in rabbit aorta. J Pharmacol Exp Ther 214:324–327
15. Cushing SD (1988) Characterization of the binding of xylamine, an irreversible inhibitor of the catecholamine transporter and depletor of neuronal noradrenergic stores. PhD Thesis, University of California, LA, 212 pp
16. 1A autoreceptors induced by neonatal DSP-4 treatment. Eur Neuropsychopharmacol 17:129–137
17. Danysz W, Jonsson G, Mohammed AK, Archer T (1985) The hind limb extension reflex is not a reliable marker of post-decapitation convulsions or spinal noradrenaline depletion in rats. Eur J Pharmacol 116:331–333
18. Davies DC, Horn G, McGabe BJ (1985) Noradrenaline and learning: effects of the noradrenergic neurotoxin DSP4 on inprinting in the domestic chick. Behav Neurosci 89:652–660
19. Delagrange P, Tadjer D, Bouyer JJ, Rougeul A, Conrath M (1989) Effect of DSP4, a neurotoxic agent, on alternative behaviour and related electrocortical activity in cat. Behav Brain Res 33:33–43
20. 3H] norepinephrine uptake by xylamine does not require monoamine oxidase activity. Life Sci 43:1871–1877
21. Dudley MW, Butcher LL, Kammerer RC, Cho AK (1981) The actions of xylamine on central noradrenergic neurons. J Pharmacol Exp Ther 217:834–840
22. Dudley MW, Howard BD, Cho AK (1990) The interaction of the beta-haloethylbenzylamines, xylamine and DSP-4 with catecholaminergic neurons. Ann Rev Pharmacol Toxicol 30:387–403
23. Féty R, Misére V, Lambás-Senas L, Renaud B (1986) Central and peripheral changes in catecholamine-synthesizing enzyme activities after systemic administration of the neurotoxin DSP-4. Eur J Pharmacol 124:197–202
24. Finnegan KT, Skratt JJ, Irwin I, DeLanney LE, Langston JW (1990) Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur J Pharmacol 184:119–126
25. Fischer JB, Waggaman LA, Ransom RW, Cho AK (1983) Xylamine, an irreversible inhibitor of norepinephrine uptake, is transported by the same uptake mechanism in cultured rat superior ganglia. J Pharmacol Exp Ther 226:650–655
26. Fornai F, Bassi L, Torracca MT, Alessandri MG, Scalori V, Corsini GU (1996) Region- and neurotransmitter dependent species and strain differences in DSP-4-induced monoamine depletion in rodents. Neurodegeneration 5:241–249
27. Fornai F, Giorgi FS, Gesi M, Chen K, Alessi MG, Shih JC (2001) Biochemical effects of the monoamine neurotoxins DSP-4 and MDMA in specific brain regions of MAO-B-deficient mice. Synapse 38:213–221
28. Fritschy JM, Grzanna R (1989) Immunochemically analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals. Neuroscience 30:181–197
29. Fritschy JM, Grzanna R (1990) Demonstration of two separate descending noradrenergic pathways in the rat spinal cord: evidence for an intragriseal trajectory of locus coeruleus axons in the superficial layers of the dorsal horn. J Comp Neurol 291:553–582
30. Fritschy JM, Grzanna R (1991a) Experimentally-induced neuron loss in the locus coeruleus of adult rats. Exp Neurol 111:123–127
31. Fritschy JM, Grzanna R (1991b) Selective effects of DSP-4 on locus coeruleus axons: are there pharmacologically different types of noradrenergic axons in the central nervous system? Prog Brain Res 88:257–268
32. Fritschy JM, Grzanna R (1992) Restoration of ascending noradrenergic projections by residual locus coeruleus neurons: compensatory response to neurotoxin-induced cell death in the adult rat brain. J Comp Neurol 321:421–441
33. Fritschy JM, Geffard M, Grzanna R (1990) The response of noradrenergic axons to systematically administered DSP-4 in the rat: an immunohistochemically study using antibodies to noradrenaline and dopamine-beta-hydroxylase. J Chem Neuroanal 3:309–321
34. Furchgott RF, Garcia PS, Wakade AR, Cervoni P (1971) Interactions of bretylium and other drugs on guinea-pig atria: evidence for inhibition of neuronal monoamine oxidase by bretylium. J Pharmacol Exp Ther 179:171–185
35. Gibson CJ (1987) Inhibition of MAO B, but not MAO A, blocks DSP-4 toxicity on central NE neurons. Eur J Pharmacol 14:135–138
36. Grzanna R, Berger U, Fritschy JM, Geffard M (1989) Acute action of DSP-4 on central norepinephrine axons: biochemical and immunohistochemical evidence for differential effects. J Histochem Cytochem 37:1435–1442
37. Haberle D, Szöko E, Hajász AS, Magyar K (2001) The effect of a low dose of (−)-deprenyl and its metabolites on DSP-4 toxicity. J Neural Transm 108:1237–1239
38. Haberle D, Magyar K, Szökö E (2002) Determination of the norepinephrine level by high-performance liquid chromatography to assess the protective effect of MAO-B inhibitors against DSP-4 toxicity. J Chromatogr Sci 40:495–499
39. Hallman H, Jonsson G (1984) Pharmacological modification of the neurotoxic action of the noradrenaline neurotoxin DSP4 on central noradrenaline neurons. Eur J Pharmacol 103:269–278
40. Hallman H, Sundström E, Jonsson G (1984) Effects of the noradrenaline neurotoxin DSP4 on monoamine neurons and their transmitter turnover in rat CNS. J Neural Transm 60:89–102
41. Harro J, Pähkla R, Modiiri A-R, Harro M, Kask A, Oreland L (1999) Dose-dependent effects of noradrenergic denervation by DSP-4 treatment on forced swimming and beta-adrenoceptor binding in the rat. J Neural Transm 106:619–629
42. Hatip-Al-Khatib I, Mishima K, Iwasaki K, Fujiwara M (2001) Microdialysates of amines and metabolites from core nucleus accumbens of freely moving rats are altered by dizocilpine. Brain Res 902:108–118
43. Heal DJ, Butler SA, Prow MR, Buckett WR (1993) Quantification of presynaptic alpha-2-adrenoceptors in rat brain after short-term DSP-4 lesioning. Eur J Pharmacol 249:37–41
44. Holt A, Berry MD, Boulton AA (2004) On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site. And effects thereby elicited. Neurotoxicology 25:251–266
45. Hormigo S, Horta Junior JD, Gômez-Neto R, Lôpez DE (2012) The selective neurotoxin DSP-4 impairs the noradrenergic projections from the locus coeruleus to the inferior colliculus in rats. Front Neural Circuits 6:41
46. Howard BD, Cho AK, Zhang MB, Koide M, Lin S (1990) Covalent labeling of the cocaine-sensitive catecholamine transporter. J Neurosci Res 26:149–158
47. Hughes ZA, Stanford SC (1998a) Evidence from microdialysis and synaptosomal studies of rat cortex for noradrenaline uptake sites with different sensitivities to SSRIs. Br J Pharmacol 124:1141–1148
48. Hughes ZA, Stanford SC (1998b) A partial noradrenergic lesion induced by DSP-4 increases extracellular noradrenaline concentration in rat frontal cortex: a microdialysis study in vivo. Psychopharmacology 133:299–303
49. Hyttel J (1982) Citalopram—pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 6:277–295
50. Jaim-Etcheverry G (1998) 2-Chloroethylamines (DSP4 and xylamine). Toxic action on noradrenergic neurones. In: Kostrzewa RM (ed) Neurotoxins. Basical and clinical applications. Human Press, Iotowa, pp 131–140
51. Jaim-Etcheverry G, Zieher LM (1980) DSP-4: a novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats. Brain Res 188:513–523
52. Jaim-Etcheverry G, Zieher LM (1983) 2-Chloroethylamines: new chemical tools for the study of noradrenergic neurons. Trends Pharmacol Sci 4:473–475
53. Jonsson G (1983) Chemical lesioning techniques: monoamine neurotoxins. In: Björklund A, Hökfelt T (eds) Handbook of chemical neuroanatomy. Methods in chemical neuroanatomy, vol I. Elsevier, New York, pp 463–507
54. Jonsson G, Hallman H, Ponzio F, Ross S (1981) DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine—a useful denervation tool for central and peripheral noradrenaline neurons. Eur J Pharmacol 72:73–188
55. Jonsson G, Hallman H, Sundström E (1982) Effects of the noradrenaline neurotoxin DSP4 on the postnatal development of central noradrenaline neurons in the rat. Neuroscience 7:2895–2907
56. 3H-DSP4, a noradrenaline neurotoxin, in central and peripheral noradrenaline neurons. J Neurochem 44:S184
57. Kalinin S, Feinstein DL, Hu HL, Huesa G, Pellegrino DA, Galea E (2006) Degeneration of noradrenergic fibers from the locus coeruleus causes tight-junction disorganisation in the rat brain. Eur J Neurosci 24:3393–3400
58. Kalir A, Sabbagh A, Youdim MB (1981) Selective acetylenic ‘suicide’ and reversible inhibitors of monoamine oxidase type A and B. Br J Pharmacol 73:55–64
59. Kammerer RC, Amiri B, Cho AK (1979) Inhibition of uptake of catecholamines by benzylamine derivatives. J Med Chem 22:352–355
60. Kask A, Harro J, Tuomaine P, Rägo L, Männistö PT (1997) Overflow of noradrenaline and dopamine in frontal cortex after [N-(2-chloro)-N-ethyl-2-bromobenzylamine] (DSP-4) treatment: in vivo microdialysis study in anaesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 355:267–272
61. Koide M, Cho AK, Howard BD (1986) Characterization of xylamine binding to proteins of PC12 pheochromocytoma cells. J Neurochem 47:1277–1285
62. Korossy-Mruk E, Kuler K, Nowak P, Szkilnik R, Rykaczewska-Czerwinska M, Kostrewa RM, Brus R (2013) Neonatal DSP-4 treatment modifies antinociceptive effects of CB1 receptor agonist methanandamine in adult rats. Neurotox Res 23:39–48
63. Krueger CA, Cook DA (1975) Synthesis and adrenergic neuron blocking properties of some alkylating analogous of bretylium. Arch Int Pharmacodyn 218:96–105
64. Landa ME, Rubio MC, Jaim-Etcheverry G (1987) The aziridinium derivative of DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine) accelerates the beating rate of isolated atria by enhancing the spontaneous release of noradrenaline. Naunyn Schmiedebergs Arch Pharmacol 336:396–402
65. 3H]desipramine binding associated with neuronal norepinephrine uptake in rat brain membranes. J Neurosci 2:1515–1525
66. Lingen B, Brüss M, Bönisch H (1994) Cloning and expression of the bovine sodium- and chloride-dependent noradrenaline transporter. FEBS Lett 342:235–238
67. Logue MP, Growdon JH, Coviella IL, Wurtman RJ (1985) Differential effects of DSP-4 administration on regional brain norepinephrine turnover in rats. Life Sci 37:403–409
68. Lyles GA, Callingham BA (1981) The effect of DSP-4 [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine] on monoamine oxidase activities in tissues of the rat. J Pharm Pharmacol 33:632–638
69. Lynch KS, Ball GF (2008) Noradrenergic deficits after processing of communication signals in female songbirds. Brain Behav Evol 72:207–214
70. Lyons WE, Fritschy JM, Grzanna R (1989) The noradrenergic neurotoxin DSP-4 eliminates the coeruleospinal projection but spares projections of the A5 and A7 groups to the ventral horn of the rat spinal cord. J Neurosci 9:1481–1489
71. Magyar K, Szende B (2004) (−)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 25:233–242
72. Mogilnicka E, Dooley DJ, Boissard CG, Delini-Stula A (1983) Altered hind limb extension in the rat after DSP-4: a useful marker of central noradrenergic depletion. Eur J Pharmacol 87:345–347
73. Nowak P, Labus L, Kostrzewa RM, Brus R (2006) DSP-4 prevents dopamine receptor priming by quinpirole. Pharmacol Biochem Behav 84:3–7
74. Nowak P, Jochem J, Zwirska-Korczala K, Josko J, Noras L, Kostrzewa RM, Brus R (2008) Ontogenetic noradrenergic lesion alters histaminergic activity in adult rats. Neurotox Res 13:79–83
75. Nyola A, Kapowich NK, Zhen J, Marden J, Reith ME, Wang DN (2010) Substrate and drug binding sites in LeuT. Curr Opin Struct Biol 20:415–422
76. Olpe HR, Laszio J, Dooley DJ, Heid J, Steinman MW (1983) Decreased activity of locus coeruleus neurons in the rat after DSP-4 treatment. Neurosci Lett 40:81–84
77. Palamarchouk VS, Zhang J-J, Zhou G, Schwiergiel AH, Dunn AJ (2000) Hippocampal norepinephrine-like voltammetric responses following infusion of corticotropin-releasing factor into the locus coeruleus. Brain Res Bull 51:319–325
78. Paton DM (1973) Mechanism of efflux of noradrenaline from adrenergic nerves in rabbit atria. Br J Pharmacol 49:614–627
79. Prieto M, Giralt MT (2001) Effects of N-(2-chlorethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on alpha2-adrenoceptors which regulate the synthesis and release of noradrenaline in the rat brain. Pharmacol Toxicol 88:152–158
80. Ransom RW, Kammerer RC, Cho AK (1982) Chemical transformations of xylamine (N-(2-chloroethyl)-N-ethyl-2-methylbenzylamine) in solution. Pharmacological activity of the species derived from this irreversible norepinephrine uptake inhibitor. Mol Pharmacol 21:380–386
81. 3H]-xylamine, an irreversible inhibitor of norepinephrine uptake. J Label Compounds Radiopharm 20:833–841
82. 3H]Xylamine accumulation by two sympathetic innervated tissues. J Neurochem 42:475–481
83. Ross SB (1976) Long-term effects of N-2-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurones in the rat brain and heart. Br J Pharmacol 58:521–527
84. 3H-bretylium in peripheral sympathomimetic nerves. Naunyn Schmiedebergs Arch Pharmacol 288:233–243
85. Ross SB, Rényi AL (1976) On the long-lasting inhibitory effect of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP 4) on the active uptake of noradrenaline. J Pharm Pharmacol 28:458–459
86. Ross SB, Johansson JG, Lindborg B, Dahlbom R (1973) Cyclizing compounds. I. Tertiary N-(2-bromobenzyl)-N-haloalkylamines with adrenergic blocking action. Acta Pharm Sueccica 10:29–42
87. Sanders JD, Happe HK, Bylund DB, Murrin LC (2011) Changes in postnatal norepinephrine alter alpha-2-adrenergic receptor development. Neuroscience 192:761–772
88. Schuerger RJ, Balaban CD (1995) N-(2-Chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) has differential efficacy for causing central noradrenergic lesions in two different rat strains: comparison between Long-Evans and Sprague-Dawley rats. J Neurosci Methods 58:95–101
89. Szökö E, Haberle D, Halász AS, Tekes K, Magyar K (2001) Protective effect of 7-nitroindazole against DSP-4 induced noradrenaline depletion in mouse hippocampus. J Neural Transm 108:407–413
90. Szot P, Miguelez C, White SS, Franklin A, Sikkema C, Wilkinson CW, Ugedo L, Rasking MA (2010) A comprehensive analysis of the effect of DSP4 on the locus coeruleus noradrenergic system in the rat. Neuroscience 166:279–291
91. 3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther 260:427–436
92. Vahaba DM, Lacey WH, Tomaszycki MI (2013) DSP-4, a noradrenergic neurotoxin, produced sex-specific effects on pairing and courtship behavior in zebra finches. Behav Brain Res 252:164–175
93. Villani L, Guarnieri E, Facchinetti F, Virgili M, Poli A (1996) Neurotoxic effects of DSP-4 on the noradrenergic system of the goldfish brain. Brain Behav Evol 47:219–224
94. Wang Y, Musich PR, Serrano MA, Zou Y, Zhang J, Zhu MY (2014) Effects of DSP4 on the noradrenergic phenotypes and its potential molecular mechanisms in SH-SYS5Y cells. Neurotox Res 25:193–207
95. Waterman SA, Harding CF (2008) Neurotoxic effects of DSP-4 on the central noradrenergic system in male zebra finches. Behav Brain Res 188:271–280
96. Weinreb O, Amit T, Riederer P, Youdim MB, Mandel SA (2011) Neuroprotective profile of the multitarget drug rasagiline in Parkinson’s disease. Int Rev Neurobiol 100:127–149
97. Wenge B, Bönisch H (2009) Interference of the noradrenergic neurotoxin DSP4 with neuronal and nonneuronal monoamine transporters. Naunyn Schmiedebergs Arch Pharmacol 380:523–529
98. Wenge B, Bönisch H (2013) The role of cysteines and histidines of the norepinephrine transporter. Neurochem Res 58:1303–1314
99. Wolfman C, Abó V, Calvo D, Medina J, Dajas F, Silveira R (1994) Recovery of central noradrenergic neurons one year after the administration of the neurotoxin DSP4. Neurochem Int 25:395–400
100. Yu PH, Davis BA, Fang J, Boulton AA (1994) Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4-induced noradrenaline depletion in the mouse hippocampus. J Neurochem 63:1820–1828
101. Yu PH, Davis BA, Zhang X, Zuo DM, Fang J, Lai CT, Li XM, Paterson IA, Boulton AA (1995) Neurochemical, neuroprotective and neurorescue effects of aliphatic N-propargylamines; new MAO-B inhibitors without amphetamine-like properties. Prog Brain Res 106:113–121
102. Yu PH, Zhang X, Zuo DM, Lai CT, Tieu K, Davis BA, Boulton AA (1998) Aliphatic N-methylpropargylamines as potential neurorescue agents. Restor Neurol Neurosci 12:113–118
103. Zaczek R, Fritschy JM, Culp S, De Souza EB, Grzanna R (1990) Differential effects of DSP-4 on noradrenaline axons in cerebral cortex and hypothalamus may reflect heterogeneity of noradrenaline uptake sites. Brain Res 522:308–314
104. Zhang X, Yu PH (1995) Depletion of NOS activity in the rat dentate gyrus neurons by DSP-4 and protection by deprenyl. Brain Res Bull 38:307–311
105. Zhang X, Zuo DM, Yu PH (1995) Neuroprotection by R(−)-deprenyl and N-(2-hexyl-N-methylpropargylamine on DSP-4, a neurotoxin. Induced degeneration of noradrenergic neurons in the rat locus coeruleus. Neurosci Lett 186:45–48
106. Zhang X, Zuo DM, Davis BA, Boulton AA, Yu PH (1996) Immunohistochemical evidence of neuroprotection by R(−)-deprenyl and N-(2-hexyl-N-methylpropargylamine on DSP-4-induced degeneration of rat brain noradrenergic axons and terminals. J Neurosci Res 43:482–489
107. Zhang J-J, Schwiergiel AH, Palamarchouk VS, Dunn AJ (1998) Intraventricular infusion of CRF increases extracellular concentrations of norepinephrine in the hippocampus and cortex as determined by in vivo voltammetry. Brain Res Bull 47:277–284
108. Zieher LM, Jaim-Etcheverry G (1980) Neurotoxicity of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSP 4) on noradrenergic neurons is mimicked by its cyclic aziridinium derivative. Eur J Pharmacol 65:249–256